This inventor holds 2 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignees: Suppremol Gmbh, Trillium Therapeutics Inc.. Active years: 2013-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Heidelberg, AU (2013)
- Victoria, AU (2014)
Company Filing History:
Years Active: 2013-2014
Title: Bruce David Wines: Innovator in Multimeric Fc Receptor Polypeptides
Introduction
Bruce David Wines is an accomplished inventor based in Victoria, Australia. He holds two patents that focus on advancements in immunology and therapeutic applications. His work has significant implications for treating immune-complex mediated inflammatory diseases.
Latest Patents
Wines' latest patents include the development of multimeric Fc receptor polypeptides. These soluble multimeric proteins or polypeptides are designed to inhibit the interaction between leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The innovative protein comprises two or more linked Fc binding regions, with at least one derived from an FcγR type receptor, specifically FcγRIIa. Additionally, the patents describe polynucleotide molecules encoding the protein or polypeptide, which can be utilized in methods for treating subjects suffering from immune-complex mediated inflammatory diseases.
Career Highlights
Throughout his career, Bruce David Wines has worked with notable companies such as Suppremol GmbH and Trillium Therapeutics Inc. His contributions to these organizations have furthered research and development in the field of immunology.
Collaborations
Wines has collaborated with various professionals in his field, including Phillip Mark Hogarth. These partnerships have enhanced the scope and impact of his research.
Conclusion
Bruce David Wines is a significant figure in the realm of immunological innovations, particularly through his work on multimeric Fc receptor polypeptides. His patents and collaborations continue to influence the development of treatments for inflammatory diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
